

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/016,850 12/14/2001		Patrick M. Hughes	D-3004	7435	
33197	7590 03/24/2006	EXAMINER			
STOUT, UX 4 VENTURE,	A, BUYAN & MULL	SPIVACK, PHYLLIS G			
IRVINE, CA			ART UNIT	PAPER NUMBER	
			1614		
			DATE MAILED: 03/24/2006		

Please find below and/or attached an Office communication concerning this application or proceeding.

		Ар	plication No.	Applicant(s)				
Office Action Summary		10	/016,850	HUGHES ET AL.				
		Ex	aminer	Art Unit				
		Phy	yllis G. Spivack	1614				
Period fo	The MAILING DATE of this communic or Reply	ation appears	on the cover sheet w	ith the correspondence a	ddress			
WHIC - Exte after - If NC - Failu Any	ORTENED STATUTORY PERIOD FO CHEVER IS LONGER, FROM THE MA nsions of time may be available under the provisions of SIX (6) MONTHS from the mailing date of this commun period for reply is specified above, the maximum stature to reply within the set or extended period for reply within the	ILING DATE 37 CFR 1.136(a). nication. tory period will app II, by statute, cause	OF THIS COMMUNI In no event, however, may a  ly and will expire SIX (6) MON the the application to become Al	CATION. reply be timely filed  NTHS from the mailing date of this of BANDONED (35 U.S.C. § 133).				
Status								
1)⊠	Responsive to communication(s) filed	on 28 Decen	nber 2005.					
2a)	· ·		on is non-final.					
·—	·							
,—	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.							
Disposit	on of Claims		•					
4)⊠	4)⊠ Claim(s) <u>1-12,14-16 and 24-26</u> is/are pending in the application.							
_	4a) Of the above claim(s) is/are withdrawn from consideration.							
5)□	) ☐ Claim(s) is/are allowed.							
6) <u></u>	Claim(s) is/are rejected.							
7)	_							
8)🖾	Claim(s) <u>1-12,14-16 and 24-26</u> are sul	bject to restric	ction and/or election	requirement.				
Applicati	on Papers							
9)□	The specification is objected to by the I	Examiner.						
			d or b) objected to	by the Examiner.				
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.  Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).								
	Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).							
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.								
Priority ι	ınder 35 U.S.C. § 119							
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).								
a)[	Allb)							
	1. Certified copies of the priority documents have been received.							
	2. Certified copies of the priority documents have been received in Application No							
	3. Copies of the certified copies of the priority documents have been received in this National Stage							
	application from the International Bureau (PCT Rule 17.2(a)).							
* See the attached detailed Office action for a list of the certified copies not received.								
Attachmen	• •							
	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTC	) () () () () () () () () () () () () ()		Summary (PTO-413) s)/Mail Date				
_	e of Draftsperson's Patent Drawing Review (PTC nation Disclosure Statement(s) (PTO-1449 or PT	•		nformal Patent Application (PT	O-152)			
	r No(s)/Mail Date	•	6)  Other:	<u> </u>				

Page 2

A Request for Continued Examination (RCE) filed December 28, 2005 is acknowledged and accepted. New claims 24-26 are presented. Claims 1-12, 14-16 and 24-26 are now under consideration.

## **ELECTION**

Claims 1-12, 14-16 and 24-26 are generic to a plurality of disclosed patentably distinct species comprising a pharmaceutical composition comprising a carrier and a pharmaceutical conjugate comprising an ophthalmically useful therapeutic component covalently coupled to an efficacy enhancing component effective in delivering the conjugate to a posterior portion of an eye, as disclosed in the subject specification. Applicants are required under 35 U.S.C. 121 to elect a single disclosed species, even though this requirement is traversed.

Should Applicants traverse on the ground that the species are not patentably distinct, Applicants should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the Examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Applicants are advised that to be complete, the reply to this requirement must include an election of the invention to be examined even though the requirement is traversed.

A telephone call to the attorney is not required where: 1) the restriction requirement is complex; 2) the application is being prosecuted pro se; or, 3) the Examiner knows from past experience that a telephone election will not be made. See MPEP 812.01.

Where the Examiner has required restriction between product and process claims and Applicant elects claims directed to the product, and a product claim is subsequently found

Art Unit: 1614

allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. Process claims that depend from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after Final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of In re Ochiai, In re Brouwer and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the Examiner before the patent issues withdraws the restriction requirement. See MPEP § 804.01.

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Phyllis G. Spivack whose telephone number is 571-272-0585. The Examiner can normally be reached on 10:30 AM-7 PM.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Christopher Low can be reached on 591-272-0951. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/016,850 Page 4

Art Unit: 1614

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

March 18, 2006

Phyllis G. Spivack PHYLLIS SP

PHYLLIS SPIVACK